Sign in

You're signed outSign in or to get full access.

Paul Matisse

Managing Director and Head of Biotech Research at Stifel Financial Corp.

Paul Matteis is a Managing Director and Head of Biotech Research at Stifel Financial Corp., specializing in biotechnology with a focus on therapeutics, neuroscience, and rare diseases. He covers an extensive list of companies including Vertex Pharmaceuticals (VRTX), Neurocrine Biosciences (NBIX), Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Vigil Neuroscience (VIGL), and Alnylam Pharmaceuticals (ALNY), and has issued recommendations with a documented 37% success rate and an average return per transaction of -3.00% based on TipRanks data. Matteis began his analyst career at Leerink, focusing on small and mid-cap biotech, after serving as a research assistant at Harvard's Division of Sleep Medicine, and joined Stifel in 2018 where he has received recognition as a 'Runner Up' in Small/Mid Cap Biotechnology by Institutional Investor from 2019 to 2024 and was named a 'Rising Star' in 2015 and 2016. He holds a degree from Skidmore College, graduated Phi Beta Kappa, and is known for his expertise in biotechnology research and stock coverage.

Paul Matisse's questions to Alkermes (ALKS) leadership

Question · Q3 2025

Paul Matisse inquired about the specific details Alkermes plans to release in the top-line Vibrance II data and the company's strategy regarding titration to mitigate side effects in future studies, particularly concerning ocular adverse events.

Answer

Richard Pops, CEO, confirmed that the top-line data structure will be revealed in the coming weeks, with full data submitted to medical meetings in 2026. He noted that decisions on phase three dosing structure have been made based on Vibrance I learnings, including the low incidence of new onset adverse events for patients previously exposed to Elixerextant.

Ask follow-up questions

Fintool

Fintool can predict Alkermes logo ALKS's earnings beat/miss a week before the call

Paul Matisse's questions to Acumen Pharmaceuticals (ABOS) leadership

Question · Q2 2025

An analyst on behalf of Paul Matisse asked about the potential differentiation of Acumen's TCR technology versus Roche's, particularly on safety, and inquired about future development plans and thoughts on preclinical Alzheimer's studies.

Answer

CEO Daniel O'Connell and President & CDO Jim Doherty highlighted two potential differentiators: JCR's carrier technology may offer a better safety profile with less anemia, and the oligomer-targeted antibody cargo could further reduce ARIA risk. Doherty noted this could allow for lower doses. Chief Medical Officer Dr. Eric Siemers added that sivernotug is a strong candidate for preclinical trials due to its low ARIA rates and discussed potential study designs using blood biomarkers for screening before larger registration trials.

Ask follow-up questions

Fintool

Fintool can predict Acumen Pharmaceuticals logo ABOS's earnings beat/miss a week before the call